CN Patent

CN117427085A — 金诺芬等老药及其组合物在抗单正链rna病毒中的应用

Assigned to Shanghai Institute of Materia Medica of CAS · Expires 2024-01-23 · 2y expired

What this patent protects

本发明涉及金诺芬等73个老药及其组合物在抗单正链RNA病毒中的应用。具体而言，本发明涉及金诺芬等多个老药及其药物组合物作为2019新型冠状病毒(SARS‑CoV‑2)3CL蛋白酶抑制剂在制备治疗和/或预防、缓解由2019新型冠状病毒感染引起的呼吸道感染、肺炎等相关疾病的药物中的用途。

USPTO Abstract

本发明涉及金诺芬等73个老药及其组合物在抗单正链RNA病毒中的应用。具体而言，本发明涉及金诺芬等多个老药及其药物组合物作为2019新型冠状病毒(SARS‑CoV‑2)3CL蛋白酶抑制剂在制备治疗和/或预防、缓解由2019新型冠状病毒感染引起的呼吸道感染、肺炎等相关疾病的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN117427085A
Jurisdiction
CN
Classification
—
Expires
2024-01-23
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Institute of Materia Medica of CAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.